A presumed hook effect in the semiquantitative DRI Oxycodone immunoassay, OXY3S (Cobas Integra, Roche Diagnostics), was investigated in 14 urine samples with gas chromatography/mass spectrometry (GC-MS) >10,000 ng/mL but OXY3S <1,000 ng/mL. These samples included the index case, a false-negative OXY3S result with >75,000 ng/mL oxycodone 1 oxymorphone by GC-MS confirmation. Patient samples needed 2-to 16-fold dilution to obtain the correct OXY3S response. The OXY3S test did not hook at highspiked concentrations of oxycodone, oxymorphone or oxymorphone3b-D-glucuronide in drug-free urine. The OXY3S test parameters were replicated in a development channel on the Cobas using DRI Reagents (Microgenics, CA, USA) and were subsequently modified. Delayed sample addition or doubling of Reagent 1 (R1: antibody/ substrate/co-factor) yielded maximal immunoassay response (>10,000 ng/mL) in 12 of 14 and 14 of 14 undiluted patient samples, respectively. Supplementation of R1 with substrate alone did not correctly recover oxycodone from any of the samples, while co-factor supplementation resulted a maximal OXY3S response in 13 of 14 samples. The remaining (index) sample could only be corrected by supplemental R1. The semiquantitative utility of the DRI Oxycodone assay is questionable. Although the precise cause of the under-recovery could not be determined, the modification presented permits reliable oxycodone determination at the high concentrations frequently seen in clinical urine samples.
Introduction
Oxycodone is a semisynthetic opioid widely used for pain management. Pain management medications accounted for about one-quarter of all the top 200 drug prescriptions filled in 2011 in the USA: hydrocodone with acetaminophen formulations ranked #1, 2, 14 and 139 by numbers of prescriptions filled; oxycodone with acetaminophen ranked #45 and 48 and oxycodone alone ranked #121 and 129 (1) . Consistent with these data, a recent study reported that hydrocodone and oxycodone (and respective metabolites) were the most prevalent drugs found among 20,089 urine specimens from chronic pain patients (2) . Like many prescription drugs, oxycodone can be the object of misuse, dependence or addiction, which can lead to an intoxication that carries significant mortality (3) . The recent increase in the number of deaths associated with opioid pain medications has raised health-care concerns (4) . From 1999 to 2008, there was a 4-fold increase in opioid sales in the USA, accompanied by a similar rise in both overdose-related deaths and substance-abuse treatment admissions related to opioids (5, 6) . It is therefore imperative to have established diagnostic tools to manage the therapeutic use of opioids as well as to detect potential diversion and abuse. Urine drug screening is one such strategy that is well established, rapid and relatively inexpensive to perform. In contrast to traditional drugs of abuse testing or toxicological testing, negative results in pain management can have serious therapeutic consequences. At our institution, we offer the Roche Partner Microgenics DRI Oxycodone assay (cutoff 300 ng/mL) (Roche Diagnostics, Indianapolis, IL, USA) as a screening test, which can be ordered as a stand-alone test or as part of a screening panel for 10 drugs that also includes the Roche Opiate (OPI; cutoff 300 ng/mL) assay (Roche Diagnostics).
The Microgenics DRI Oxycodone reagent is a homogeneous enzyme multiplied immunoassay technique (EMIT) assay in which there is competition for limiting antibody between oxycodone in the urine sample and oxycodone conjugated to the enzyme glucose-6-phosphate dehydrogenase (G6PDH). This test consists of preincubation of patient samples with Reagent 1 (R1: oxycodone antibody, G6P substrate and NAD þ cofactor), followed by the addition of Reagent 2 (R2: oxycodonelabeled G6PDH). As urine oxycodone binds to the antibody, active G6PDH enzyme is released and substrate usage quantitated by monitoring the rate of increase in absorbance at 340 nm. Our specific application of this test, OXY3S, is a semiquantitative assay based on a five-point calibration curve (0-1,000 ng/mL), extended by an automatic dilution to 10,000 ng/mL. OXY3S is reported to be 103% cross-reactive with oxymorphone, but ,0.1% with noroxycodone and noroxymorphone (7, 8) . The Roche OPI kit utilizes kinetic interaction of microparticles in solution (KIMS) technology. Here, microparticles coated with morphine antibodies aggregate in the presence of a soluble morphine conjugate solution, becoming turbid. Addition of urine containing a cross-reacting target drug sequesters antibody and partially inhibits the aggregation; the amount of drug present can be inferred by monitoring the decrease in end-point absorbance at 552 nm. We use the OPI kit in a semiquantitative mode based on a four-point calibration curve (0-600 ng/mL), extended by an automatic dilution to 30,000 ng/mL. OPI is reported to crossreact with morphine (100%), codeine (125%), hydromorphone (57%), hydrocodone (48%) and minimally with oxycodone (3.1%) and oxymorphone (1.9%) (9) .
Positive patient results for either OXY3S or OPI immunoassays reflex confirmation testing by gas chromatography/mass spectrometry (GC-MS). This test detects codeine, morphine, hydrocodone, hydromorphone, oxycodone, oxymorphone and dihydrocodeine with a cutoff at 20 ng/mL. Although we report results for both OXY3S and OPI as either screen positive or screen negative, the immunoassay value determines the dilution required for GC-MS. Confirmation tests for samples with OXY3S .10,000 ng/mL or OPI .30,000 ng/mL are run neat and also diluted 20Â prior to GC-MS to ensure efficient hydrolytic recovery, extraction and derivatization, and to reduce the potential for carry-over.
Recently, while confirming an OPI-positive (4,546 ng/mL) specimen by GC-MS we found these results: morphine 2,276 ng/mL, hydromorphone 93 ng/mL, oxycodone 58,975 ng/mL and oxymorphone 18,381 ng/mL. Surprisingly, OXY3S was negative (268 ng/mL), and upon review, the immunoassay and GC-MS results repeated similarly. The GC-MS results were consistent with the patient's prescriptions for morphine (extended release 60 mg twice a day), and oxycodone (15 mg every 4 h), with hydromorphone and oxymorphone present as their respective metabolites. Fortunately, the OPI-positive result caused by morphine present in this sample reflexed the confirmation assay and we were able to avoid missing the patient's true drug exposure. According to cross-reactivity data supplied by the manufacturer, the oxycodone and oxymorphone content of the sample should have been sufficient to trigger an OPI-positive result regardless of its morphine content: using the 300 ng/mL cutoff and the aforementioned cross-reactivities of oxycodone and oxymorphone, oxycodone .9,677 ng/mL or oxymorphone .15,789 ng/mL should produce a positive OPI test result.
This incident prompted us to be vigilant, but we have not seen another OXY3S negative sample with a positive confirmation for oxycodone in over 18 months. However, we observed that a significant number of samples having OXY3S results ,1,000 ng/ mL resulted in oxycodone and/or oxymorphone concentrations well above 10,000 ng/mL when confirmed by GC-MS. These discordant results led us to hypothesize that we were observing a hook effect in the OXY3S assay. A hook effect in an EMIT assay is considered unlikely, as complete antibody or substrate consumption is believed to result in maximal absorbance (either using end-point or rate measurements) rather than a hook. Indeed, a hook effect in an EMIT assay has rarely been documented (10) . We therefore considered the potential reasons for the observed under-recovery by the OXY3S assay, and devised experiments to test each hypothesis.
Materials and methods

Specimen collection and dilutions
Residual urine samples (n ¼ 13) with oxycodone test results ,1,000 ng/mL by OXY3S, but .10,000 ng/mL by GC-MS (total oxycodone þ oxymorphone), were randomly selected over a 3-month period for study, in addition to the index case (Table I) . Each sample was serially 2-fold diluted in drug-free urine and analyzed by OXY3S until the test yielded either a maximal test response (i.e. .10,000 ng/mL), or a result that did not increase further on subsequent dilution.
Gas chromatography/mass spectrometry For the Opiates GC-MS assay, 1.0 mL samples, calibrators and controls with D3-codeine internal standard were added, hydrolyzed with b-glucuronidase (Helix pomatia, Sigma G-7770) at pH 5, followed by the formation of selected oximes by derivatization with hydroxylamine, solid-phase extraction (CLEAN-SCREENw, UCT-ZSDAU020, PA) and TMS derivatization (modified from Broussard et al. (11) by the use of a 25 m Â 0.2 mm HP5 with a 0.5-mm film (Agilent) analytical column with helium carrier gas at 1 mL/min; the oven temperature was operated on from 180 to 3108C). GC-MS was performed on an Agilent 6890 GC with a 5973 Mass Spectrometer (Palo Alto, CA, USA). Mass spectra were collected in selected ion monitoring mode (SIM; one target quantitative ion and two qualifiers for each compound plus the internal standard). The test is considered positive for a compound if its retention time and qualifier ions are within +0.5 min and +20%, compared with those of the calibrator, respectively, and the quantitative value is !20 ng/mL. To determine the amount of glucuronide metabolites present, samples were processed as before, but omitting the hydrolysis step. The difference between the nonhydrolyzed and the total hydrolyzed concentrations was taken to indicate the concentration of the glucuronide-conjugated metabolites.
To assess possible interference from a broader spectrum of drugs and/or metabolites in the samples, the urines were processed by a single-step basic organic extraction into ethyl acetate and analyzed on an Agilent 6890 Gas Chromatograph equipped with a 5975 Mass Spectrometer. The analytical column was a 25 m Â 0.2 mm HP5 with a 0.5-mm film (Agilent) with helium carrier gas at 1 mL/min. The oven temperature was operated on from 90 to 3258C over 18 min; splitless inlet temperature was 2758C. Electron impact mass spectra were collected in scan mode across the range 38-550 a.m.u. Drug identification was made using the Agilent Data Analysis librarymatching software.
Salicylates assay
Aspirin metabolites were determined in urine samples by Trinder's reagent as described (12) in a semiquantitative mode with in-house calibration standards made from sodium salicylate.
EMIT assay parameters DRI Reagents were purchased from Microgenics (Fremont, CA, USA) and placed into an empty user-defined chemistry development assay cassette (Cobas Integra, Roche Diagnostics). The following test parameters (summarized in Table II) were programmed into the development channel application on the analyzer: 'OXY3S': standard mode; 60 mL R1, 60 mL R2 and 6 mL of sample were added at cycles 5, 18 and 45, respectively; spectrophotometric measurements made between cycles 55 -65 (identical to those provided by Roche for the OXY3S assay); 'OXYDEV': S late mode; 60 mL R1, 6 mL of sample and 60 mL R2 were added at cycles 5, 18 and 104, respectively; spectrophotometric measurements made between cycles 116-136; 'OXYDEV þ R1': S late mode; 120 mL R1, 6 mL of sample and 60 mL R2 were added at cycles 5, 18 and 104, respectively; spectrophotometric measurements made between cycles 116-136; 'OXY3S þ R1': standard mode; 120 mL R1, 60 mL R2 and 6 mL of sample were added at cycles 5, 18 and 45, respectively; spectrophotometric measurements made between cycles 55 -65. OXY3S was further modified by the addition of supplemental substrate and co-factor; G6P and NADP þ (Sigma) added in 20 mmol/mL and 3 mmol/L increments, respectively.
Results
Correlation between OXY3S and GC-MS results, and serial sample dilutions A convenience sample of 100 consecutive positive OXY3S urine samples were reviewed and stratified into three groups by their OXY3S results: Group 1, 300-1,000 ng/mL (n ¼ 78), Group 2, 1,001-10,000 ng/mL (n ¼ 10) and Group 3, .10,000 ng/mL (n ¼ 12). Comparison was then made with the total oxycodone þ oxymorphone GC-MS results ( Figure 1) . All of the samples in Group 2 (GC-MS range 921-3,620, mean 1,862 and SD 768 ng/mL) and Group 3 (GC-MS range 7,148-34,515, mean 17,915 and SD 9,900 ng/mL) were correctly categorized by their OXY3S result. In contrast, the samples in Group 1 showed a very wide distribution of GC-MS values (GC-MS range 66-267,760, mean 13,116 and SD 34,086 ng/mL). Significantly, only 34 of the 78 samples ( just 44%) in this group were correctly categorized by their OXY3S value. Twenty-six (33%) samples had values between 1,000 and 10,000 ng/mL by GC-MS and 18 (23%) had GC-MS values exceeding 10,000 ng/mL. This later group of 18 samples did not receive correct handling for the dilution protocol for GC-MS. Significantly, of the 27 samples with GC-MS results .10,000 ng/mL, two-thirds had OXY3S values ,1,000 ng/mL.
During our vigilance period, we randomly selected 13 residual urine samples (in addition to the index case) having low OXY3S values (range 317-971 ng/mL) and oxycodone þ oxymorphone .10,000 ng/mL by GC-MS (range 30,966-207,325 ng/mL oxycodone þ oxymorphone; Table I ). Some specimens contained additional opioids (Supplementary Table SI Each of the 14 samples was serially diluted 2-fold in drug-free urine and was then measured by OXY3S. For every sample, the dilution yielded higher concentrations than the undiluted samples: six samples required a 2Â dilution, six other samples required a 4Â dilution and two samples each required a 8Â and 16Â dilution to resolve the apparent hook effect (Figure 1 ). This experiment presented further evidence for under-recovery in the OXY3S assay and raised the level of suspicion for a hook effect.
OXY3S recovery of high concentrations of control oxycodone, oxymorphone and glucuronide-conjugated oxymorphone spiked into urine samples We first investigated the possibility that this was a classic hook effect caused simply by high concentrations of either oxycodone and/or oxymorphone in the patients' urine samples. We spiked negative human control urine (to minimize possible matrix effects) with oxycodone or oxymorphone (Cerilliant, TX, USA) at a concentration (500,000 ng/mL) that greatly exceeded Figure 1 . Under-recovery of oxycodone by the OXY3S EMIT assay. (A) Distribution of OXY3S result compared with GC-MS oxycodone þ oxymorphone result in 100 consecutive OXY3S screen-positive samples. Samples were stratified by OXY3S result into three groups: Group 1, 300-1,000 ng/mL (n ¼ 78), Group 2, 1,001-10,000 ng/mL (n ¼ 10) and Group 3, .10,000 ng/mL (n ¼ 12). Dotted circles represent the theoretical region where samples should plot if GC-MS and OXY3S results are in agreement ( +20% tolerance). (B) Dilution required for each sample in order to resolve the hook effect using OXY3S: further dilution yielded a similar recovered value.
the highest total recovered oxycodone þ oxymorphone by GC-MS (207,325 ng/mL) in any of the patients' samples. OXY3S recovery was close to 100% (mean 108.3 + 14.7%) for the solutions with concentrations ,10,000 ng/mL (122-7,813 ng/mL), and for the six solutions with concentrations .10,000 ng/mL (15,625 -500,000 ng/mL), OXY3S correctly reported values as .10,000 ng/mL (Supplementary Table SII) .
Spiking urine with oxycodone and oxymorphone could not reproduce the hook effect that occurred with our samples. Urine samples, however, are a more complicated matrix containing not only oxycodone and oxymorphone, but also demethylated and conjugated metabolites. In our set of 14 samples, the glucuronide conjugates accounted for 47-100% (mean 74%) and 57-100% (mean 90%) of the total oxycodone and oxymorphone content, respectively (values given in Table I ), assuming that the release of glucuronide conjugates is close to 100%. The response of OXY3S to glucuronide conjugates was tested by analyzing serial 2-fold dilutions of oxymorphone-3b-D-glucuronide (Cerilliant) spiked at 50,000 ng/mL into negative human control urine. This spike concentration was higher than all but one of our 14 samples. The measured OXY3S values were again .10,000 ng/mL in the solutions with concentrations in the range of 12,500-50,000 ng/mL, and recovery was near 100% (mean 114.4 + 10.7%) in the solutions with concentration in the range of 48-6,250 ng/mL (Supplementary Table SII) . We assume that oxycodone glucuronide behaves similarly (but it was not tested due to unavailability). Thus, the hypothesis that the hook might be due to large concentrations of glucuronide conjugates is also disproved, leading us to suspect that the under-recovery in OXY3S may be caused by interfering substances in the samples.
OXY3S under-recovery due to interfering substances
Immunoassays are prone to influence by the presence of both endogenous components or drugs or their metabolites in the specimens. When these cross-react with the antisera falsepositive results may occur. Those that produce either a high background absorbance or an absorbance decrease during the spectrophotometric measurement period of the OXY3S assay will cause under-recovery. The manufacturer does not indicate any known drug interferences (7, 8) in the OXY3S assay. Comprehensive drug screening of the patients' urine samples by GC-MS identified a broad range of medications (Supplementary  Table SI) , all of which are commonly encountered in our patient population. Salicyluric acid (SUA), the main urine metabolite of aspirin, has been reported to cause false-negative EMIT assays when present above 2,000 mg/L (13, 14) since SUA reduces the molar absorptivity of NADH at 340 nm, resulting in a falsely reduced measurement of the NADH generated. Neither oxycodone nor oxymorphone has significant absorbance at 340 nm (15) . Only three of our patient samples, including the index case, were positive for salicylates, but all below 2,000 mg/L (concentrations shown in Supplementary Table SI) ; the remaining 11 did not contain significant amounts of aspirin metabolites, suggesting that an alternative explanation was needed.
All of our 14 patients (eight males and six females) were adults, age 26 -73 years. Only one of the 14 patients (#5) was admitted via the Emergency Department (ED); all the other samples were collected during routine monitoring visits for pain management or substance-abuse treatment. None was administered naloxone or prescribed suboxone (buprenorphine plus naloxone), which has been shown to cross-react significantly with the Immunalysis Corporation homogeneous enzyme immunoassay oxycodone assay, although reportedly only minimally with the Microgenics DRI Oxycodone assay (16) . We did not identify common diagnoses among our patients; eight patients were being treated for cancer-associated pain (two chronic myelogenous leukemia, one Hodgkins lymphoma and five solid tumors), but none of these were multiple myeloma patients who may have high concentrations of Bence-Jones proteins. Of the noncancer patients, two were trauma, one had spinal compression and one each had arthritis and fibromyalgia. Review of the prescribed medications listed for each patient revealed no drugs or drug groups in common. None had contrast administered for investigational procedures.
Finally, we extracted the timed-absorbance data for each sample during OXY3S analysis from the Cobas Integra database, compared with them to the calibrator and control samples, and saw no abnormally high initial absorbance, or decline in absorbance once either the sample or R2 was added. Instead, we found that the kinetic reaction increased over the entire measurement period, albeit at a slower rate than expected, thus arguing against substrate/reagent depletion, and underestimating the true concentration of drug in the sample. Since we were still unable to identify the reason for under-recovery of OXY3S or the presence of a common possibly interfering compound, we sought to investigate whether modifications of the EMIT parameters could improve oxycodone recovery in the OXY3S assay.
Resolution of the hook effect
We previously used the Microgenics DRI Oxycodone reagents as a development channel application (OXYDEV; Cobas Integra 800) for 4 years and did not notice any discrepancy with the GC-MS results. OXY3S and OXYDEV use the same reagents with similar volumes of sample and reagents, but differ in their order and timing of addition (Table II) . Because the instrument parameters for OXY3S cannot be modified, we set up OXY3S and OXYDEV as development channel application. Calibration and controls were run after every modification before testing the patient samples. Set-up as a development channel, OXY3S again produced aberrant results (,1,000 ng/mL) for all samples (Table III) , even though these had been frozen and thawed between measurements. While OXYDEV accurately determined oxycodone (.10,000 ng/mL) in 12 of 14 samples (86%) (Table III) , this test takes an additional 7 min compared with OXY3S. Next, we doubled the volume of R1 (OXYDEV þ R1) and re-analyzed the samples that had not already been corrected, which now yielded correct results (.10,000 ng/mL). Moreover, a 2-fold dilution of these two samples using OXYDEV also produced a .10,000 ng/mL result, a marked improvement over the 1:16 and 1:8 dilution required with OXY3S. In OXYDEV, the sample is added last, and kinetic measurement occurs later, suggesting that preequilibration of R1 and R2 may be important for accurate EMIT recovery of oxycodone. The addition of twice R1 in OXY3S (OXY3S þ R1) also correctly determined maximal concentrations in all samples (Table III) , whereas adding only 1.5Â R1 or a smaller urine sample volume was not successful. Thus, adding excess R1 resolved the apparent hook effect independently of the order of reagent addition or the time of kinetic measurement. Since R1 is a multicomponent reagent, we sought to investigate which one was insufficient in OXY3S. Supplementing R1 with substrate and co-enzyme has been reported previously to extend EMIT reagent kits (17) . First, we supplemented R1 in OXY3S with G6P (20 mmol/mL), and although the calibration curve was altered, it did not correct the under-recovery in the patient samples. However, further supplementation of R1 with NADP þ in 3 mmol/L increments, resulted in a .10,000 ng/mL OXY3S concentration in 13 samples: in 10 samples after supplementation with 3 mmol/L NADP þ and then in a further three samples with the addition of 6 mmol/L of the co-factor (Table III) . Only the index sample remained underrecovered, but was now above the cutoff (658 ng/mL). The addition of more co-factor (9 mmol/L) or substrate (40 mmol/L) did not improve the recovery in this sample. Thus, we concluded that, while insufficient co-factor causes under-recovery in the OXY3S assay, in the index sample more antibodies were also necessary to obtain a reliable result.
Discussion
We identified a false-negative DRI Oxycodone immunoassay result in a patient sample, which fortunately was discovered during GC-MS confirmation triggered by a positive OPI screening assay. The OPI positive in this case was attributed to the presence of morphine and hydromorphone (2,276 and 93 ng/mL), and to cross-reactivity from the extremely large oxycodone and oxymorphone concentrations also found in this sample (58,975 and 18,381 ng/mL, respectively). A large body of literature has accumulated around false-positive and false-negative immunoassay results, reflecting the seriousness of such events (reviewed in Reisfield et al. (18) ).
Drug testing can be performed in a variety of specimens: urine, blood, oral fluid, hair, etc. Urine drug testing (UDT) has been the industry gold standard for more than two decades, as it has the advantages of large sample volume, ease of collection, low cost, wide availability, fast results and longer length of drug detection than some other fluids. UDT also has limitations related to interindividual differences in drug metabolism, intraindividual differences in hydration status, amenability of specimens to adulteration and inability to correlate dosage with urine drug concentration or clinical effect. The goals of any individual UDT program are dictated by the context in which it is used. UDT is widely used in clinical practice for the detection of a suspected ingestion based on presenting symptomatology, often with unclear history. A false-negative result here might lead to failure to treat or to administer an antidote (although for suspected opioid toxicity naloxone is administered empirically), or unnecessary and expensive diagnostic tests. When UDT is used to promote a drug-free workplace, a false-positive test rarely results in termination since confirmation testing is usually mandatory, but other disciplinary action or stigma attached to a delayed result does sometimes occur. On the other hand, a falsenegative will not only fail to identify violators, but also places all workers at an increased risk of injury. When used as a tool for the surveillance of patients enrolled in substance-abuse recovery programs, a false-negative result for a prescribed medication may lead to accusations of diversion of medication for financial gain. In the pain management field, UDT is used to monitor compliance to the prescribed drug regimen. In this scenario, a positive result is expected, and a negative test result may lead to expulsion from the program. Therefore, it is important here to avoid both false-positive and false-negative results. While most regulatory agencies mandate UDT screening by immunoassay and confirmation of all positive screening results using mass spectrometry to minimize the risk of false-positive results, only the largest clinical laboratories are able to offer these two levels of testing. On the other hand, negative results are only rarely followed up.
Following the coincidental discovery of a false-negative DRI Oxycodone immunoassay result in a patient sample during GC-MS confirmation triggered by a positive OPI screening assay, we became more vigilant. As a result of our investigations, we report here a high incidence of inconsistency with the semiquantitative OXY3S assay. Almost one-quarter of samples (18 of 78 Group 1 samples) with low-positive OXY3S results (.300 ng/mL cutoff but ,1,000 ng/mL) in our convenience set of 100 samples had very high concentrations of oxycodone and oxymorphone by GC-MS confirmation (range 10,289 -267,760 ng/mL, mean 49,173 ng/mL and SD 58,670 ng/mL). Another study also concluded that the same test kit, when operated on a Hitachi 917 analyzer, did not offer reliable quantitative results. They also found a low incidence (23% to our 33%) of samples giving the correct DRI Oxycodone result when they contained very high oxycodone concentrations (.10,000 ng/ mL) by GC-MS; 77% significantly under-recovered by DRI (19) . Such an observation with a widely used product is indeed worrisome.
While we were fortunate to detect our false-negative OXY3S result because of the presence of cross-reacting compounds in the OPI assay (morphine and hydromorphone), not all falsenegative specimens can be picked up in this way. Our OPI and OXY3S tests are offered independently, and therefore not always requested together. Using the cross-reactivity data provided for the OPI assay, we calculated from the GC-MS measured oxycodone and oxymorphone concentrations for each sample whether a positive OPI result should be observed. All 14 of our samples were expected to be OPI positive; 9 exclusively from cross-reactivity by oxycodone and oxymorphone (only 8 of these tested positive), and the other 5 due to the presence of other opiates (all 5 tested positive) (Supplementary Table SI) .
There is rising public concern over the misuse and diversion of prescription pain medicines, and of oxycodone in particular (20, 21) . US ED visits related solely to nonmedical use of opioids went from 144,644 to 305,885 between 2004 and 2008, which represents a 111% increase. During this same period, ED visits related to oxycodone products alone increased by 152%. Urine drug screening is rapid, relatively inexpensive and widely available, but reagents must be formulated to eliminate both falsepositive and false-negative results. During the time when the main role of screening tests was in the detection of drug use, the economics of testing focused attention on eliminating false positives. Now that pain management testing is evolving as its own specialty, the equal importance of false-negative results is being appreciated and deserves further attention (18) .
Based on our investigations, several options are available to the analyst for preventing aberrant low results with this DRI OXY3S assay. The under-recovery is resolved completely with manual dilution of samples prior to analysis. However, testing multiple dilutions of the same sample increases both cost and processing time and may lead to labeling errors. Extension of the test reaction time by 7 min corrects most of the aberrant results. Although the time to first result is delayed, analytical throughput is not decreased since samples are processed in parallel. However, most laboratories are unable to alter the manufacturer-defined test parameters. Similarly, relying on the presence of cross-reacting opioids in the OPI assay to pick up true oxycodone-positive samples is highly undesirable. While we were able to demonstrate that simple addition of more R1 into the reaction mixture effectively resolved the under-recovery, we remain unable to explain why an EMIT assay would hook. We notified the manufacturer about the observed under-recovery of this assay and sent aliquots of two of our samples to them. The semiquantitative utility of the DRI Oxycodone assay is questionable, but the modified application presented in this study would allow a reliable determination of oxycodone if adopted by the manufacturer.
Supplementary data
Supplementary data is available at Journal of Analytical Toxicology online.
